EN
Home/United States/Blog/Does Medicaid cover Wegovy or Zepbound? Which states cover GLP‑1s for weight, and which dropped them
USUnited States Coverage and eligibility

Does Medicaid cover Wegovy or Zepbound? Which states cover GLP‑1s for weight, and which dropped them

Why coverage is optional, the 13 states KFF counted in January 2026, the four that stopped, and how to check your own state’s rules.

Written for the United States, from US sources.

The short answer

It depends on your state. Federal law lets state Medicaid programs leave out weight-loss drugs, though they must cover GLP‑1s for diabetes. KFF counted 13 states covering GLP‑1s for obesity in January 2026, down from 16 in October 2025, after California, New Hampshire, Pennsylvania and South Carolina stopped.

Key takeaways

  • Covering GLP‑1s for weight is optional for state Medicaid programs, while coverage is required when the drugs are approved for diabetes, KFF explains.1
  • KFF counted 13 state Medicaid programs covering GLP‑1s for obesity in January 2026, down from 16 in October 2025.1
  • California, New Hampshire, Pennsylvania and South Carolina ended coverage after October 2025; North Carolina dropped it in October 2025 and brought it back in December.1
  • Gross Medicaid spending on GLP‑1s for all uses rose from about $1 billion in 2019 to nearly $9 billion in 2024, before rebates.1
  • Where Medicaid does cover GLP‑1s for weight, use is typically controlled by prior authorization, which can limit access further.1
Before you go further
  • State rules change often. This is KFF’s snapshot from January 2026; your state Medicaid program has the current rules.
  • This post can’t tell you whether you qualify. Your state, your plan and your prescriber decide that.
  • The medicines carry the same risks however they are paid for: see our side effects guide.
On this page
  1. Why doesn’t every Medicaid program cover GLP‑1s for weight?
  2. Which states covered GLP‑1s for weight in 2026?
  3. Which states dropped coverage, and why?
  4. Will the federal BALANCE Model change this?
  5. How do you check what your state covers?
  6. Questions people ask
  7. How we researched this
  8. Sources

Why doesn’t every Medicaid program cover GLP‑1s for weight?

Because federal law lets states leave weight-loss drugs out of Medicaid, while drugs approved for diabetes must be covered.1

Under the Medicaid drug rebate rules, weight-loss drugs are among “a small group of drugs that can be excluded from coverage”, KFF explains. That makes obesity coverage “optional for states, while coverage is required for drugs approved for the treatment of diabetes”. KFF says the same applies to some heart and sleep apnea uses.1

In practice, Medicaid can cover Ozempic or Mounjaro for type 2 diabetes in every state, while Wegovy or Zepbound for weight depends on where you live.1 For Zepbound’s separate sleep apnea approval, see Zepbound for sleep apnea.

Which states covered GLP‑1s for weight in 2026?

KFF counted 13 state Medicaid programs covering GLP‑1s for obesity under fee-for-service in January 2026.1

Fee-for-service means the state pays providers directly, rather than through a managed-care plan. KFF’s state map, January 2026:1

Delaware
Kansas
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
North Carolina
Rhode Island
Tennessee
Utah
Virginia
Wisconsin

States KFF shows as covering GLP‑1s for obesity treatment, January 2026, in alphabetical order. KFF notes Utah’s funding was limited to fiscal year 2026.1

Seven more states (Connecticut, Louisiana, New Hampshire, New Mexico, North Dakota, Pennsylvania and Texas) reported covering at least one weight-loss drug, but not a GLP‑1.1

Lists like this go out of date. In November 2025, Stateline reported that Michigan would limit coverage from 2026 to people who are “morbidly obese”.2 Check with your state before relying on any list.

Which states dropped coverage, and why?

California, New Hampshire, Pennsylvania and South Carolina ended it after October 2025, and North Carolina dropped it before reinstating it; cost is the reason states give.1,2

  1. Oct 202516 state Medicaid programs covered GLP‑1s for obesity, KFF’s survey found.1
  2. Oct 2025North Carolina ended coverage, citing state funding shortfalls.2
  3. Dec 2025North Carolina reinstated coverage.1
  4. Jan 202613 states, after California, New Hampshire, Pennsylvania and South Carolina ended coverage.1

Name the incentive: these drugs are expensive and widely used. KFF found gross Medicaid spending on GLP‑1s rose from about $1 billion in 2019 to nearly $9 billion in 2024. Gross spending per prescription reached $1,000 in 2024.1 Those figures are before rebates, and KFF notes states typically receive substantial rebates on brand drugs.1

A North Carolina health department spokesperson told Stateline that coverage “would be reconsidered if Medicaid is fully funded”.2

Free toolWork out a 6- or 12-month cost

Pick a medicine and a dose plan to see a year at makers’ self-pay prices. No sign-up.

Open the calculator

Will the federal BALANCE Model change this?

Possibly in some states: CMS is negotiating GLP‑1 prices for state Medicaid programs that choose to join, from May 2026 to January 2027.3

The BALANCE Model is a CMS program in which the government negotiates prices and terms with the makers. States can join on a rolling basis from May 1, 2026, to January 1, 2027. Applications closed on July 31, 2026.3

We found no published list of the states taking part as of October 12, 2026, from CMS or KFF. Joining is voluntary, so it doesn’t oblige a state to cover these drugs.

If you have both Medicare and Medicaid, Medicare’s $50 GLP‑1 Bridge may apply if you have Part D and meet its rules. It runs outside your Part D plan.4

RisksThe risks, in brief
  • Stomach effects. In the main trials, about 44 in 100 people on Wegovy 2.4 mg injection felt sick (nausea), against about 16 in 100 on a dummy injection (placebo);5 about 25 to 29 in 100 people on Zepbound felt sick, against about 8 in 100 on a dummy injection.6 It mostly comes while the dose goes up.
  • Gallstones were reported in 16 in 1,000 people on Wegovy injection, against 7 in 1,000 on placebo;5 11 in 1,000 on Zepbound, against 10 in 1,000 on placebo, with gallbladder inflammation in 7 in 1,000 against 2 in 1,000.6
  • Pancreatitis (an inflamed pancreas): severe stomach pain that won’t go away and may spread to the back. The labels say to stop the medicine if it is suspected.5,6
  • Thyroid warning. The labels carry a boxed warning: these medicines are not for people with a personal or family history of medullary thyroid cancer (MTC) or MEN 2, a rare inherited condition that causes gland tumors.5,6
  • Dehydration from vomiting or diarrhea can harm the kidneys. Tell the team before any surgery or sedation, because a slower-emptying stomach raises the risk of breathing in food or fluid.5,6
  • Pregnancy. The Wegovy label says to stop at least 2 months before a planned pregnancy;5 Zepbound can make birth-control pills less reliable for about 4 weeks after starting and after each dose step.6
Full detail in our side effects guide →
Get help now: call 911 or go to the ER for severe stomach pain that won’t go away, with or without vomiting (it can be pancreatitis), or for swelling of the face or throat or trouble breathing. For a possible overdose, Poison Control is 1-800-222-1222.5,6,7

How do you check what your state covers?

Ask your state Medicaid program or your Medicaid health plan whether GLP‑1s for weight are covered, which brands, and what the prior authorization needs.1

Questions to ask, by phone or through your plan’s member services:

  • Does my plan cover GLP‑1 medicines for weight management, or only for diabetes?
  • Which brands are on the preferred drug list?
  • What does the prior authorization need: BMI, conditions, a weight program?
  • How long does approval last, and what is needed to renew?

The makers’ $25 savings cards don’t work with Medicaid.8,9 If your state doesn’t cover these drugs for weight, the cash prices are in GLP‑1 costs without insurance. How a prior authorization works is in prior authorization, step by step.

Questions people ask

Does Medicaid cover Wegovy?

For weight, only in some states. KFF counted 13 state Medicaid programs covering GLP‑1s for obesity in January 2026, usually with prior authorization.1

Does Medicaid cover Ozempic?

For type 2 diabetes, yes: KFF says coverage of drugs approved for diabetes is required.1

Why did California stop covering GLP‑1s for weight loss?

KFF lists California among four states that ended coverage after October 2025. States cutting coverage have pointed to cost.1,2

Can I use the Zepbound savings card with Medicaid?

No. Lilly’s savings card excludes anyone in a state or federal health program, including Medicaid.8

What is the Medicaid BALANCE Model?

A CMS program in which states can choose to join and CMS negotiates GLP‑1 prices and terms with the makers. States could join from May 2026 to January 2027.3

How we researched this

State coverage comes from KFF’s January 2026 analysis and its state map notes, checked on October 12, 2026. North Carolina’s and Michigan’s changes come from a dated Stateline report.1,2

BALANCE details come from KFF’s May 2026 brief. We searched CMS and KFF for the states that joined and found no published list.3

Before you move on

  • Ask your state or plan: weight, or diabetes only?
  • Find out which brand is preferred.
  • Ask what the prior authorization needs.
  • Check renewal rules before you start.
  • If you also have Medicare, check the GLP‑1 Bridge.

More from the US blog

About GLP Guidebook

The monthly US update

An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: FDA approvals and warnings, Medicare and Medicaid changes, and makers’ price changes. How we write

Was this post easy to understand?

Sources

  1. KFF. Medicaid coverage of and spending on GLP-1s, including Figure 1 state map and notes. January 16, 2026. Link
  2. Stateline. States retreat from covering drugs for weight loss. November 28, 2025 (also republished by Kiowa County Press). Link
  3. KFF. What to know about the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. May 11, 2026. Link
  4. Medicare.gov. Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month (fact sheet). CMS Product No. 12234, June 2026. Link
  5. Novo Nordisk. Wegovy (semaglutide) injection and tablets: US prescribing information. Revised 06/2026. Link
  6. Eli Lilly. Zepbound (tirzepatide): US prescribing information. Revised 8/2026. Link
  7. Poison Control (National Capital Poison Center). Poison help line 1-800-222-1222. Link
  8. Eli Lilly. Zepbound coverage and savings, for health care providers. Checked Oct 12, 2026. Link
  9. Novo Nordisk. Price your Wegovy (NovoCare): self-pay prices by dose, new-patient offer and savings-card terms. Checked Oct 12, 2026. Link

Last checked Oct 12, 2026 · Next review due Apr 12, 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your doctor, pharmacist or prescriber before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write